Autogene cevumeran
BioNTech's personalised vaccine, notable for a small pancreatic cancer study where vaccine responders stayed cancer-free for years.
Phase 1 (Rojas/Balachandran, Nature 2023; 3-year follow-up 2025): half of resected PDAC patients mounted T-cell responses and had markedly longer recurrence-free survival than non-responders. Phase 2 IMCODE003 in adjuvant PDAC and trials in colorectal (ctDNA+ after surgery) and melanoma. BioNTech/Genentech.
1.Up to 20 neoantigens are selected from the resected tumour's mutations
- Route
- Intravenous infusion (lipoplex)
- Schedule
- Priming: 8 weekly doses; boosters at 6-week intervals; with atezolizumab and mFOLFIRINOX in adjuvant PDAC
- Monitoring
- Infusion reactions, cytokine-related fever
Source: clinicaltrials.gov/study/NCT05968326. Doses are for orientation; the current label governs.
| Adverse event |
|---|
| Pyrexia |
| Chills |
| Fatigue |
| Infusion-related reactions |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (phase 2 IMCODE003) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Autogene cevumeran" OR ABSTRACT:"Autogene cevumeran" OR TITLE:"BNT122" OR ABSTRACT:"BNT122" OR TITLE:"RO7198457" OR ABSTRACT:"RO7198457") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Autogene cevumeran, not a curated reading list.